A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
Fludarabine-based regimens have overall response rates (ORR) of 90-95% in untreated chronic lymphocytic leukemia (CLL), but almost all patients inevitably relapse. Given the promising activity of lenalidomide in relapsed/refractory CLL, we studied the combination of fludarabine and rituximab (FR) followed by lenalidomide in untreated disease (n=22). Patients received three cycles (C) of FR (F 25 mg/m 2 days (D) 1-5, R 375 mg/m 2 D1). Those who responded received three more cycles of FR followeddoi:10.7243/2052-434x-3-2 fatcat:waadyhrabbdghahwgrafhwpa6m